Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors

the COG Central Nervous System Committee

Research output: Contribution to journalArticlepeer-review

4 Citations (Web of Science)

Abstract

Tumors of the central nervous system (CNS) are a leading cause of morbidity and mortality in the pediatric population. Molecular characterization in the last decade has redefined CNS tumor diagnoses and risk stratification; confirmed the unique biology of pediatric tumors as distinct entities from tumors that occur in adulthood; and led to the first novel targeted therapies receiving Food and Drug Administration (FDA) approval for children with CNS tumors. There remain significant challenges to overcome: children with unresectable low-grade glioma may require multiple prolonged courses of therapy affecting quality of life; children with high-grade glioma have a dismal long-term prognosis; children with medulloblastoma may suffer significant short- and long-term morbidity from multimodal cytotoxic therapy, and approaches to improve survival in ependymoma remain elusive. The Children's Oncology Group (COG) is uniquely positioned to conduct the next generation of practice-changing clinical trials through rapid prospective molecular characterization and therapy evaluation in well-defined clinical and molecular groups.

Original languageEnglish
Article numbere30600
JournalPediatric Blood and Cancer
Volume70
Issue numberS6
DOIs
Publication statusPublished - Sept 2023

Fingerprint

Dive into the research topics of 'Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors'. Together they form a unique fingerprint.

Cite this